Pelthos Therapeutics Inc.
For the period ended Dec 31, 2024. Filed Mar 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 27, 2025
PTHS$9.37+0.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, 2024 | December 31, 2023 | |
|---|---|---|
| ASSETS | ||
| CURRENT ASSETS | ||
| Cash | $513,443 | $96,391 |
| Prepaid expenses | 65,300 | — |
| Due from Chromocell Corporation | 40,400 | — |
| Deferred offering costs | 750,000 | — |
| TOTAL CURRENT ASSETS | 1,369,143 | 96,391 |
| TOTAL ASSETS | $1,369,143 | $96,391 |
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||
| CURRENT LIABILITIES | ||
| Accounts payable and accrued expenses | $1,897,127 | $4,620,925 |
| Accrued compensation | — | 645,947 |
| Investor Note, net of debt discount | — | 316,324 |
| Loan payable, net of debt discount | 2,054,202 | 202,279 |
| Loan payable - related party, net of debt discount | 131,868 | 750,082 |
| Due to Chromocell Corporation | — | 5,386 |
| TOTAL CURRENT LIABILITIES | 4,083,197 | 6,540,943 |
| TOTAL LIABILITIES | 4,083,197 | 6,540,943 |
| COMMITMENTS AND CONTINGENCIES | ||
| STOCKHOLDERS’ DEFICIT | ||
| Preferred stock Series A, $0.0001 par value, 700,000 shares authorized, 0 and 600,000 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively | — | 60 |
| Preferred stock Series C, $0.0001 par value, 5,000 shares authorized, 2,600 and 0 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively | — | — |
| Common stock, $0.0001 par value, 200,000,000 shares authorized, 6,103,813 and 3,906,300 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively | 613 | 391 |
| Additional paid in capital | 18,760,320 | 7,074,646 |
| Accumulated deficit | (21,474,987) | (13,519,649) |
| TOTAL STOCKHOLDERS’ DEFICIT | (2,714,054) | (6,444,552) |
| TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT | $1,369,143 | $96,391 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.